These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

197 related articles for article (PubMed ID: 37399447)

  • 1. Application of the multiphase optimisation strategy (MOST) to optimise HIV prevention targeting people on medication for opioid use disorder (MOUD) who have cognitive dysfunction: protocol for a MOST study.
    Mistler CB; Shrestha R; Gunstad J; Collins L; Madden L; Huedo-Medina T; Sibilio B; Copenhaver NM; Copenhaver M
    BMJ Open; 2023 Jun; 13(6):e071688. PubMed ID: 37399447
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Providing medication for opioid use disorder and HIV pre-exposure prophylaxis at syringe services programs via telemedicine: a pilot study.
    McKellar MS; Des Marais AC; Chen H; Choi Y; Lilly R; Ayers D; Bennett J; Kestner L; Perry B; Poley S; Corneli A; Meade CS; Sachdeva N
    Harm Reduct J; 2024 Mar; 21(1):69. PubMed ID: 38532395
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Study protocol for an efficacy trial of the "PrEP for Health" intervention to increase HIV PrEP use among people who inject drugs.
    Bazzi AR; Bordeu M; Baumgartner K; Sproesser DM; Bositis CM; Krakower DS; Mimiaga MJ; Biello KB
    BMC Public Health; 2023 Mar; 23(1):513. PubMed ID: 36932369
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Contingency Management and Pre-Exposure Prophylaxis Adherence Support Services (CoMPASS): A hybrid type 1 effectiveness-implementation study to promote HIV risk reduction among people who inject drugs.
    Sung ML; Viera A; Esserman D; Tong G; Davidson D; Aiudi S; Bailey GL; Buchanan AL; Buchelli M; Jenkins M; John B; Kolakowski J; Lame A; Murphy SM; Porter E; Simone L; Paris M; Rash CJ; Edelman EJ
    Contemp Clin Trials; 2023 Feb; 125():107037. PubMed ID: 36460267
    [TBL] [Abstract][Full Text] [Related]  

  • 5. "Take services to the people": strategies to optimize uptake of PrEP and harm reduction services among people who inject drugs in Uganda.
    Kamusiime B; Beima-Sofie K; Chhun N; Nalumansi A; Nalukwago GK; Kasiita V; Twesige CC; Kansiime R; Muwonge TR; Kyambadde P; Kadama H; Mudiope P; Glick S; Lambdin B; Mujugira A; Heffron R
    Addict Sci Clin Pract; 2024 Feb; 19(1):13. PubMed ID: 38395940
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Delivering integrated strategies from a mobile unit to address the intertwining epidemics of HIV and addiction in people who inject drugs: the HPTN 094 randomized controlled trial protocol (the INTEGRA Study).
    Goodman-Meza D; Shoptaw S; Hanscom B; Smith LR; Andrew P; Kuo I; Lake JE; Metzger D; Morrison EAB; Cummings M; Fogel JM; Richardson P; Harris J; Heitner J; Stansfield S; El-Bassel N;
    Trials; 2024 Feb; 25(1):124. PubMed ID: 38360750
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Using nominal group technique to identify barriers and facilitators to preventing HIV using combination same-day pre-exposure prophylaxis and medications for opioid use disorder.
    Eger WH; Altice FL; Lee J; Vlahov D; Khati A; Osborne S; Wickersham JA; Bohonnon T; Powell L; Shrestha R
    Harm Reduct J; 2022 Oct; 19(1):120. PubMed ID: 36307817
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The Impact of COVID-19 on Access to HIV Prevention Services Among Opioid-Dependent Individuals.
    Mistler CB; Curley CM; Rosen AO; El-Krab R; Wickersham JA; Copenhaver MM; Khati A; Shrestha R
    J Community Health; 2021 Oct; 46(5):960-966. PubMed ID: 33770334
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Systematic review of HIV treatment adherence research among people who inject drugs in the United States and Canada: evidence to inform pre-exposure prophylaxis (PrEP) adherence interventions.
    Bazzi AR; Drainoni ML; Biancarelli DL; Hartman JJ; Mimiaga MJ; Mayer KH; Biello KB
    BMC Public Health; 2019 Jan; 19(1):31. PubMed ID: 30621657
    [TBL] [Abstract][Full Text] [Related]  

  • 10. M
    Martel-Laferrière V; Feaster DJ; Metsch LR; Schackman BR; Loignon C; Nosyk B; Tookes H; Behrends CN; Arruda N; Adigun O; Goyer ME; Kolber MA; Mary JF; Rodriguez AE; Yanez IG; Pan Y; Khemiri R; Gooden L; Sako A; Bruneau J
    Trials; 2022 Apr; 23(1):341. PubMed ID: 35461260
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Evaluation of an inner city HIV pre-exposure prophylaxis service tailored to the needs of people who inject drugs.
    Grimshaw C; Boyd L; Smith M; Estcourt CS; Metcalfe R
    HIV Med; 2021 Nov; 22(10):965-970. PubMed ID: 34585494
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Rationale and design of an integrated bio-behavioral approach to improve adherence to pre-exposure prophylaxis and HIV risk reduction among opioid-dependent people who use drugs: The CHRP-BB study.
    Shrestha R; Altice FL; Sibilio B; Ssenyonjo J; Copenhaver MM
    Contemp Clin Trials; 2019 Jul; 82():77-84. PubMed ID: 31229618
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Perspectives on HIV pre-exposure prophylaxis (PrEP) utilization and related intervention needs among people who inject drugs.
    Biello KB; Bazzi AR; Mimiaga MJ; Biancarelli DL; Edeza A; Salhaney P; Childs E; Drainoni ML
    Harm Reduct J; 2018 Nov; 15(1):55. PubMed ID: 30419926
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Qualitative inquiry into perceptions of HIV pre-exposure prophylaxis among people who inject drugs living with hepatitis C in Seattle, WA, USA.
    Barry MP; Austin EJ; Bhatraju EP; Glick SN; Stekler JD; Tung EL; Hansen RN; Williams EC; Gojic AJ; Pickering EI; Tsui JI
    Harm Reduct J; 2022 Nov; 19(1):121. PubMed ID: 36320005
    [TBL] [Abstract][Full Text] [Related]  

  • 15. HIV Pre-Exposure Prophylaxis Prevention Awareness, Willingness, and Perceived Barriers among People Who Inject Drugs in Los Angeles and San Francisco, CA, 2016-2018.
    Walters SM; Kral AH; Simpson KA; Wenger L; Bluthenthal RN
    Subst Use Misuse; 2020; 55(14):2409-2419. PubMed ID: 32962490
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The Pre-exposure Prophylaxis (PrEP) Care Cascade in People Who Inject Drugs: A Systematic Review.
    Mistler CB; Copenhaver MM; Shrestha R
    AIDS Behav; 2021 May; 25(5):1490-1506. PubMed ID: 32749627
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Limited Knowledge and Mixed Interest in Pre-Exposure Prophylaxis for HIV Prevention Among People Who Inject Drugs.
    Bazzi AR; Biancarelli DL; Childs E; Drainoni ML; Edeza A; Salhaney P; Mimiaga MJ; Biello KB
    AIDS Patient Care STDS; 2018 Dec; 32(12):529-537. PubMed ID: 30311777
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Brief Report: Use of Pre-Exposure Prophylaxis to Prevent Rapid HIV Transmission Among People Who Inject Drugs in Rural Counties in the United States: A Modeling Study.
    Jacka BP; Nolen S; Bessey SE; Zang X; Goedel WC; Yedinak JL; Marshall BDL
    J Acquir Immune Defic Syndr; 2022 Dec; 91(5):449-452. PubMed ID: 36150038
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Provider Implicit Bias in Prescribing HIV Pre-exposure Prophylaxis (PrEP) to People Who Inject Drugs.
    Dubov A; Krakower DS; Rockwood N; Montgomery S; Shoptaw S
    J Gen Intern Med; 2023 Oct; 38(13):2928-2935. PubMed ID: 36964426
    [TBL] [Abstract][Full Text] [Related]  

  • 20. 'PrEP is not ready for our community, and our community is not ready for PrEP': pre-exposure prophylaxis for HIV for people who inject drugs and limits to the HIV prevention response.
    Guise A; Albers ER; Strathdee SA
    Addiction; 2017 Apr; 112(4):572-578. PubMed ID: 27273843
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.